The difference between retatrutide and semaglutide, explained clearly

Step 1: understand what each medicine actually targets

Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that signals fullness to the brain, slows gastric emptying, and reduces appetite. That single-pathway action underpins both the Wegovy injection and, for type 2 diabetes treatment only, Ozempic — two products with the same molecule but entirely different UK licences. The NHS medicine page for semaglutide sets this out clearly.

Retatrutide is something different in structure. It is a triple receptor agonist, acting on GIP, GLP-1 and glucagon receptors simultaneously. In theory, that third pathway (glucagon) could increase energy expenditure on top of reducing intake, a combination no licensed UK medicine currently replicates. The pharmacology is genuinely novel. Whether that translates into meaningfully better outcomes for most patients, at an acceptable side-effect profile, is precisely what ongoing phase-3 trials are designed to establish. Anyone weighing up the two approaches may find it helpful to read our detailed look at whether retatrutide is actually better than semaglutide before drawing conclusions from trial headlines.

A question our prescribers hear most weeks: "Is retatrutide coming out soon, and should I wait?" The honest answer is that no timeline for a UK licence application has been confirmed publicly, and waiting for an unlicensed medicine is not a clinical strategy anyone can responsibly recommend.

Step 2: compare what the evidence actually says so far

The comparison below summarises the key factual differences. Trial figures for retatrutide are from published phase-2 data only and should be interpreted cautiously; phase-3 results may differ, and no head-to-head trial of retatrutide versus semaglutide 2.4mg has been published.

The STEP 1 trial figures for semaglutide are drawn from the NEJM publication of that study. The 7.2mg figure reflects the MHRA's April 2026 approval of the higher-dose pen. For context on where semaglutide sits alongside other licensed agents, the retatrutide versus semaglutide comparison page goes deeper on the mechanistic evidence.

Step 3: know what this means for anyone looking at treatment now

If you are considering weight management treatment today, retatrutide is not an option through any legitimate UK route. It is not licensed, not prescribable, and not obtainable from a regulated pharmacy. Anyone offering it in the UK is operating outside the law.

Semaglutide as Wegovy is licensed, has a strong evidence base, and is available through a private prescription following clinical assessment. NICE recommended it under TA875 within specialist NHS services; privately, the eligibility criteria are set by the licensed indication (adults with a BMI of 30 or above, or 27 or above with a relevant weight-related condition). Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

If you want to understand what's currently available and where semaglutide fits alongside other licensed options, the weight-loss treatment overview gives a grounded starting point. Tirzepatide (Mounjaro) is the other licensed injectable option; for a sense of how different GLP-1 class agents compare in structure and effect, this page on GLP-1 versus semaglutide adds useful context. A broader look at how liraglutide relates to semaglutide is covered on the liraglutide comparison page for anyone researching the class more thoroughly, and patients curious about how dulaglutide fits into the same family can find a clear explanation on the page covering the difference between dulaglutide and semaglutide.

When retatrutide does reach regulators (and phase-3 results are anticipated in the next couple of years) the picture may shift. Until then, the clinical decision is made from what is licensed, evidenced, and safely available. Speak to our prescribers to find out which current option fits your health profile.